The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

New documents clarify how the FDA plans to regulate AI-enabled devices, experts say, but several important questions remain ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Intuitive is buying businesses that distribute its da Vinci and Ion surgical robots to establish a direct presence in Italy, ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

Johnson & Johnson's fourth-quarter revenues and profit were driven by strong cancer drug sales. The company announced ...

Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.

Rick Wise, an analyst from Stifel Nicolaus, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated price ...

Johnson & Johnson is like the Fort Knox of dividend stocks. The healthcare company has an AAA bond rating. That's tied for ...

From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.